|
|
|
|
|
Etonogestrel
drug data and news
Etonogestrel drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Etonogestrel | ||
| Brand Names/Synonyms | ETONOGESTREL; Etonogestrel [Usan:Inn]; Implanon; ORG 3236 | ||
| Indication | For use as a female contraceptive (depot) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Etonogestrel is used as a female contraceptive. Etonogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Etonogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. | ||
| Mechanism Of Action | Etonogestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like etonogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. | ||
| Etonogestrel News (When available) |
Akzo Nobel planning IPO for pharma business Feb 7, 2006 Akzo Nobel planning IPO for pharma business Feb 7, 2006 Organon Launches First Nationwide Direct-To-Consumer Advertising ... Nov 8, 2005 Lower Estrogen Exposure and Fewer Patient Telephone Callbacks ... Sep 9, 2005 Lower Estrogen Exposure and Fewer Patient Telephone Callbacks ... Sep 9, 2005 Taking one for the team Aug 30, 2005 First line of defence Aug 30, 2005 After 45 Years, Descendants of "The Pill" Rule Contraceptive Roost Jul 29, 2005 Contraception During Perimenopause Jun 22, 2005 Akzo Nobel's Organon to meet with FDA about Implanon action letter ... Jun 21, 2005 Organon Receives Approvable From FDA for Contraceptive Implant Jun 21, 2005 Contraception During Perimenopause Jun 22, 2005 Akzo Nobel's Organon to meet with FDA about Implanon action letter ... Jun 21, 2005 Organon Receives Approvable From FDA for Contraceptive Implant Jun 21, 2005 NuvaRing.com Receives Prestigious Award Nomination from ... Apr 26, 2005 Nuvaring®: No Interaction with Broad-Spectrum Antibiotics Avoids ... Apr 6, 2005 NuvaRing®: at least as reliable as the pill yet with once-a-month ... Mar 11, 2005 On the Pill and Fed Up with Irregular Bleeding? New Results Show ... Feb 15, 2005 | ||
| Dosage Forms | Vaginal ring (slow-release) | ||
| Drug_Category | Contraceptives; ATC:G03AC08 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Etonogestrel: Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. John's wort, temazepam, theophylline (Theo-Dur), and vitamin C. | ||
| Toxicity | Symptoms of overdose include nausea, vomiting, vaginal bleeding, and other menstrual irregularities. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one | ||
| Chemical Formula | C22H28O2 | ||
| Molecular Weight | 324.457 g/mol | ||
| Smiles String | CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34 | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.848 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Etonogestrel.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nuv1624.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00766 | ||
| CAS Registry Number | 54048-10-1 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:181766 | ||
| PharmGKB ID | PA10908 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2253186 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |